Literature DB >> 25066124

Complement-dependent modulation of antitumor immunity following radiation therapy.

Michelle Elvington1, Melissa Scheiber1, Xiaofeng Yang1, Katherine Lyons2, Dustin Jacqmin2, Casey Wadsworth1, David Marshall2, Kenneth Vanek2, Stephen Tomlinson3.   

Abstract

Complement is traditionally thought of as a proinflammatory effector mechanism of antitumor immunity. However, complement is also important for effective clearance of apoptotic cells, which can be an anti-inflammatory and tolerogenic process. We show that localized fractionated radiation therapy (RT) of subcutaneous murine lymphoma results in tumor cell apoptosis and local complement activation. Cotreatment of mice with tumor-targeted complement inhibition markedly improved therapeutic outcome of RT, an effect linked to early increases in apoptotic cell numbers and increased inflammation. Improved outcome was dependent on an early neutrophil influx and was characterized by increased numbers of mature dendritic cells and the subsequent modulation of T cell immunity. Appropriate complement inhibition may be a promising strategy to enhance a mainstay of treatment for cancer.
Copyright © 2014 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25066124      PMCID: PMC4137409          DOI: 10.1016/j.celrep.2014.06.051

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  46 in total

1.  Natural adjuvants: endogenous activators of dendritic cells.

Authors:  S Gallucci; M Lolkema; P Matzinger
Journal:  Nat Med       Date:  1999-11       Impact factor: 53.440

2.  Endogenous IL-17 as a mediator of neutrophil recruitment caused by endotoxin exposure in mouse airways.

Authors:  Masahide Miyamoto; Olof Prause; Margareta Sjöstrand; Martti Laan; Jan Lötvall; Anders Lindén
Journal:  J Immunol       Date:  2003-05-01       Impact factor: 5.422

Review 3.  Innate and adaptive immune response to apoptotic cells.

Authors:  Yufeng Peng; David A Martin; Justin Kenkel; Kang Zhang; Carol Anne Ogden; Keith B Elkon
Journal:  J Autoimmun       Date:  2007-09-20       Impact factor: 7.094

Review 4.  C1q receptors: regulating specific functions of phagocytic cells.

Authors:  A J Tenner
Journal:  Immunobiology       Date:  1998-08       Impact factor: 3.144

5.  Complement-dependent inflammation and injury in a murine model of brain dead donor hearts.

Authors:  Carl Atkinson; Juan C Varela; Stephen Tomlinson
Journal:  Circ Res       Date:  2009-10-08       Impact factor: 17.367

6.  The receptor for activated complement factor 5 (C5aR) conveys myocardial ischemic damage by mediating neutrophil transmigration.

Authors:  Martin Mueller; Christine Herzog; Jan Larmann; Martina Schmitz; Denise Hilfiker-Kleiner; J Engelbert Gessner; Gregor Theilmeier
Journal:  Immunobiology       Date:  2013-03-28       Impact factor: 3.144

7.  IgM antibodies to apoptosis-associated determinants recruit C1q and enhance dendritic cell phagocytosis of apoptotic cells.

Authors:  Yifang Chen; Yong-Beom Park; Ekta Patel; Gregg J Silverman
Journal:  J Immunol       Date:  2009-05-15       Impact factor: 5.422

8.  Role of T lymphocytes in tumor response to radiotherapy.

Authors:  Sandra Demaria; Silvia C Formenti
Journal:  Front Oncol       Date:  2012-08-24       Impact factor: 6.244

9.  C1q and mannose binding lectin engagement of cell surface calreticulin and CD91 initiates macropinocytosis and uptake of apoptotic cells.

Authors:  C A Ogden; A deCathelineau; P R Hoffmann; D Bratton; B Ghebrehiwet; V A Fadok; P M Henson
Journal:  J Exp Med       Date:  2001-09-17       Impact factor: 14.307

10.  Antitumor activity of recombinant interleukin 6 in mice.

Authors:  J J Mulé; J K McIntosh; D M Jablons; S A Rosenberg
Journal:  J Exp Med       Date:  1990-03-01       Impact factor: 14.307

View more
  25 in total

1.  Chemotherapeutic tumor microparticles combining low-dose irradiation reprogram tumor-promoting macrophages through a tumor-repopulating cell-curtailing pathway.

Authors:  Yanling Sun; Zu'an Zheng; Huafeng Zhang; Yuandong Yu; Jingwei Ma; Ke Tang; Pingwei Xu; Tiantian Ji; Xiaoyu Liang; Degao Chen; Xun Jin; Tianzhen Zhang; Zhixiong Long; Yuying Liu; Bo Huang
Journal:  Oncoimmunology       Date:  2017-03-31       Impact factor: 8.110

2.  Differential transcriptome of tolerogenic versus inflammatory dendritic cells points to modulated T1D genetic risk and enriched immune regulation.

Authors:  T Nikolic; N J C Woittiez; A van der Slik; S Laban; A Joosten; C Gysemans; C Mathieu; J J Zwaginga; B Koeleman; B O Roep
Journal:  Genes Immun       Date:  2017-08-10       Impact factor: 2.676

3.  White Matter is the Predilection Site of Late-Delayed Radiation-Induced Brain Injury in Non-Human Primates.

Authors:  Rachel N Andrews; Gregory O Dugan; Ann M Peiffer; Gregory A Hawkins; David B Hanbury; J Daniel Bourland; Robert E Hampson; Samuel A Deadwyler; J Mark Clinea
Journal:  Radiat Res       Date:  2019-01-29       Impact factor: 2.841

4.  Radiotherapy supports tumor-specific immunity by acute inflammation.

Authors:  Laura Surace; Nicole Angelika Scheifinger; Anurag Gupta; Maries van den Broek
Journal:  Oncoimmunology       Date:  2015-06-24       Impact factor: 8.110

5.  Complementing the tumor-specific immunity in tumor radiotherapy.

Authors:  Linjie Zhao; Shengtao Zhou
Journal:  Ann Transl Med       Date:  2016-08

Review 6.  Complement in cancer: untangling an intricate relationship.

Authors:  Edimara S Reis; Dimitrios C Mastellos; Daniel Ricklin; Alberto Mantovani; John D Lambris
Journal:  Nat Rev Immunol       Date:  2017-09-18       Impact factor: 53.106

Review 7.  Deciphering the Intricate Roles of Radiation Therapy and Complement Activation in Cancer.

Authors:  Jacob Gadwa; Sana D Karam
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-07-03       Impact factor: 7.038

8.  Complement Activation via a C3a Receptor Pathway Alters CD4+ T Lymphocytes and Mediates Lung Cancer Progression.

Authors:  Jeff W Kwak; Jennifer Laskowski; Howard Y Li; Maria V McSharry; Trisha R Sippel; Bonnie L Bullock; Amber M Johnson; Joanna M Poczobutt; Alexander J Neuwelt; Stephen P Malkoski; Mary C Weiser-Evans; John D Lambris; Eric T Clambey; Joshua M Thurman; Raphael A Nemenoff
Journal:  Cancer Res       Date:  2017-11-08       Impact factor: 12.701

9.  Low miR-187 expression promotes resistance to chemoradiation therapy in vitro and correlates with treatment failure in patients with esophageal adenocarcinoma.

Authors:  Niamh Lynam-Lennon; Becky A Bibby; Ann Marie Mongan; Laure Marignol; Christian N Paxton; Katherine Geiersbach; Mary P Bronner; Jacintha O'Sullivan; John Reynolds; Stephen G Maher
Journal:  Mol Med       Date:  2016-05-23       Impact factor: 6.354

Review 10.  Tissue-targeted complement therapeutics.

Authors:  Stephen Tomlinson; Joshua M Thurman
Journal:  Mol Immunol       Date:  2018-07-07       Impact factor: 4.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.